ABBV AbbVie (ABBV) Q1 FY25 earnings call
AbbVie delivered a strong Q1 FY25, driven by exceptional performance from its ex-Humira portfolio, particularly Skyrizi and Rinvoq, leading to an upward revision of full-year EPS guidance. Despite faster-than-expected Humira erosion and ongoing macroeconomic pressures on aesthetics, the company is strategically investing in its pipeline, including new obesity programs and oncology ADCs, to secure long-term growth beyond its core immunology franchise. Management emphasized its robust U.S. manufacturing footprint and commitment to innovation amidst evolving policy landscapes.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.